Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008698:Mesylates / Q000009:adverse effects*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012894:Sleep Stages / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D008698:Mesylates; C001441:improsan